Rekah Pharmaceutical Industry Past Earnings Performance
Past criteria checks 3/6
Rekah Pharmaceutical Industry's earnings have been declining at an average annual rate of -32.4%, while the Pharmaceuticals industry saw earnings growing at 9.3% annually. Revenues have been growing at an average rate of 9.5% per year. Rekah Pharmaceutical Industry's return on equity is 4.6%, and it has net margins of 2.3%.
Key information
-32.4%
Earnings growth rate
-32.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 35.1% |
| Revenue growth rate | 9.5% |
| Return on equity | 4.6% |
| Net Margin | 2.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up
Jul 11
Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden
Jul 05Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year
Dec 14Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet
Sep 12Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)
Jul 19Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit
Apr 13We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt
May 12Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today
Apr 09Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?
Mar 12Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 19
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?
Jan 29Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock
Jan 08How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?
Dec 18Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%
Nov 30Revenue & Expenses Breakdown
How Rekah Pharmaceutical Industry makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 332 | 8 | 74 | 4 |
| 30 Jun 24 | 324 | 7 | 74 | 4 |
| 31 Mar 24 | 332 | -6 | 75 | 4 |
| 31 Dec 23 | 322 | -7 | 71 | 4 |
| 30 Sep 23 | 315 | -8 | 68 | 4 |
| 30 Jun 23 | 309 | -3 | 64 | 4 |
| 31 Mar 23 | 299 | -2 | 61 | 3 |
| 31 Dec 22 | 292 | -2 | 60 | 3 |
| 30 Sep 22 | 287 | 4 | 60 | 3 |
| 30 Jun 22 | 275 | 3 | 56 | 3 |
| 31 Mar 22 | 272 | 5 | 53 | 3 |
| 31 Dec 21 | 264 | 7 | 50 | 2 |
| 30 Sep 21 | 262 | 5 | 47 | 2 |
| 30 Jun 21 | 273 | 9 | 46 | 2 |
| 31 Mar 21 | 263 | 10 | 45 | 1 |
| 31 Dec 20 | 265 | 11 | 46 | 2 |
| 30 Sep 20 | 240 | 7 | 47 | 2 |
| 30 Jun 20 | 221 | 5 | 47 | 1 |
| 31 Mar 20 | 215 | 4 | 47 | 1 |
| 31 Dec 19 | 196 | 3 | 46 | 2 |
| 30 Sep 19 | 201 | 6 | 46 | 2 |
| 30 Jun 19 | 195 | 5 | 45 | 2 |
| 31 Mar 19 | 196 | 7 | 46 | 3 |
| 31 Dec 18 | 199 | 8 | 45 | 3 |
| 30 Sep 18 | 202 | 0 | 49 | 3 |
| 30 Jun 18 | 206 | -8 | 51 | 3 |
| 31 Mar 18 | 208 | -11 | 52 | 2 |
| 31 Dec 17 | 201 | -21 | 51 | 2 |
| 30 Sep 17 | 204 | -31 | 54 | 3 |
| 30 Jun 17 | 208 | -22 | 56 | 3 |
| 31 Mar 17 | 209 | -20 | 56 | 2 |
| 31 Dec 16 | 218 | -11 | 58 | 2 |
| 30 Sep 16 | 185 | 8 | 46 | 1 |
| 30 Jun 16 | 195 | 8 | 50 | 1 |
| 31 Mar 16 | 204 | 5 | 55 | 1 |
| 31 Dec 15 | 210 | 3 | 58 | 1 |
| 30 Sep 15 | 258 | -7 | 75 | 3 |
| 30 Jun 15 | 259 | -7 | 77 | 2 |
| 31 Mar 15 | 265 | -5 | 76 | 2 |
| 31 Dec 14 | 216 | -1 | 60 | 1 |
| 30 Sep 14 | 273 | 6 | 78 | 0 |
| 30 Jun 14 | 269 | 7 | 77 | 0 |
| 31 Mar 14 | 274 | 8 | 80 | 0 |
| 31 Dec 13 | 270 | 8 | 80 | 0 |
Quality Earnings: REKA has high quality earnings.
Growing Profit Margin: REKA became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: REKA has become profitable over the past 5 years, growing earnings by -32.4% per year.
Accelerating Growth: REKA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: REKA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.1%).
Return on Equity
High ROE: REKA's Return on Equity (4.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 02:50 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rekah Pharmaceutical Industry Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|